Table 2.

Summary of base-case analysis: clinical and economic outcomes of treatments with insulin lispro vs. regular insulin

Description of outcome	Lispro	Regular insulin	Difference
Life expectancy (years)	11.90 (0.179)	11.844 (0.167)	0.06
Quality-adjusted life expectancy (years)	7.601 (0.117)	7.497 (0.107)	0.105
Lifetime direct medical costs (£)	70 576 (1774)	72 529 (1793)	−1953
ICER based on life expectancy		Dominant
ICER based on quality-adjusted life expectancy		Dominant

ICER, incremental cost-effectiveness ratio.

Values shown are means with standard deviation in parentheses.

All costs and clinical outcomes are discounted at 3.5%per annum.